Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 1.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 768,740 shares of the company’s stock after buying an additional 12,783 shares during the quarter. Geode Capital Management LLC’s holdings in Kodiak Sciences were worth $2,007,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KOD. SG Americas Securities LLC acquired a new stake in shares of Kodiak Sciences in the third quarter worth $33,000. Meeder Asset Management Inc. acquired a new stake in Kodiak Sciences during the 2nd quarter worth about $36,000. Sanctuary Advisors LLC acquired a new stake in Kodiak Sciences during the 2nd quarter worth about $36,000. LJI Wealth Management LLC raised its stake in shares of Kodiak Sciences by 21.3% during the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock valued at $45,000 after buying an additional 3,000 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Kodiak Sciences in the 2nd quarter valued at about $127,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Trading Down 3.9 %

Shares of NASDAQ:KOD opened at $9.20 on Thursday. The company has a market capitalization of $484.14 million, a price-to-earnings ratio of -2.52 and a beta of 2.11. Kodiak Sciences Inc. has a 12-month low of $2.18 and a 12-month high of $11.60. The business has a 50-day moving average price of $7.42 and a 200 day moving average price of $4.39.

Analyst Ratings Changes

A number of brokerages have issued reports on KOD. Barclays boosted their price target on Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Friday, November 15th. Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, December 9th. Finally, HC Wainwright restated a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Friday, November 15th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.